Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want to see whether ZYNRELEF revenue offsets R&D spending on next-gen oncology injectables? The answer lives in the Heron Therapeutics quarterly earnings report 10-Q filing—but combing through biotech jargon takes time. Stock Titan鈥檚 AI decodes every document the moment it hits EDGAR, giving you pipeline milestones, cash-runway metrics, and Heron Therapeutics SEC filings explained simply.
- Heron Therapeutics Form 4 insider transactions real-time – follow executive stock moves minutes after submission.
- Heron Therapeutics annual report 10-K simplified – AI highlights CINVANTI sales, royalty obligations, and trial costs.
- Heron Therapeutics 8-K material events explained – grasp FDA decisions or financings without legalese.
Need answers fast? Type questions like 鈥淗ow to read Heron Therapeutics鈥� 10-K?鈥� or 鈥淲here is the Heron Therapeutics proxy statement executive compensation section?鈥� —our platform serves curated links plus plain-English commentary. You鈥檒l also find Heron Therapeutics insider trading Form 4 transactions and an at-a-glance Heron Therapeutics earnings report filing analysis so you can monitor guidance shifts tied to the biochronomer platform.
Whether you鈥檙e tracking Heron Therapeutics executive stock transactions Form 4 before earnings, comparing quarter-over-quarter R&D ratios, or simply understanding Heron Therapeutics SEC documents with AI, Stock Titan delivers real-time alerts, exportable tables, and side-by-side comparisons. Spend less time scrolling and more time acting on clear insights.
Heron Therapeutics (HRTX) Q2-25 10-Q highlights
- Revenue: Net product sales rose 3.3% YoY to $37.2 m; 1H-25 sales up 7.7% to $76.1 m. Growth was driven by Zynrelef (+40% YoY) and Aponvie (+142%), offset by lower Sustol.
- Margins: Q2 gross margin expanded to 73% (prior-year 71%). Operating expenses fell 9% to $29.0 m on lower R&D (-34%) and SG&A (-15%), narrowing the operating loss to $1.6 m from $6.4 m.
- Profitability: Q2 net loss improved to $2.4 m (-$0.02/sh) vs -$9.2 m (-$0.06/sh). For 1H-25 the company posted a small profit of $0.3 m versus a -$12.4 m loss a year earlier.
- Liquidity: Cash & short-term investments were $40.6 m (down from $59.3 m YE-24) after operating cash burn of $19.7 m YTD. Inventory rose $19.8 m to $73.0 m (mainly Cinvanti and Zynrelef).
- Balance sheet: Total debt $175.2 m, comprised of $149.8 m 1.5% senior converts due May-26 and $25.4 m drawn under the Hercules working-capital facility. Stockholders鈥� deficit improved to -$27.3 m.
- Refinancing plan: On 8-8-25 the company signed agreements to upsize the Hercules facility to $150 m, issue $35 m 5% converts due 2031, sell $29.7 m in equity/Series A preferred, and exchange/repay the existing $150 m converts. Closings expected 8-12-25, eliminating near-term maturities and adding working capital.
Outlook: Management believes current cash plus proceeds from the refinancing will fund operations for 鈮�12 months. Key drivers remain Zynrelef uptake, successful launch of the vial-access needle, and execution of the Hercules credit milestones.
Heron Therapeutics (HRTX) restructures and adds liquidity via four coordinated transactions dated 8 Aug 25.
Debt amendment: Working Capital Facility with Hercules rises to $150 m (tranche 1 $110 m closing; tranche 2 $20 m available through 15 Dec 26; tranche 3 $20 m by 30 Sep 27). Maturity shifts to the earlier of 1 Sep 30 or 180 days before any new convert maturity. Interest = Prime (7.5 % floor)+1.95 % cash +1.0 % PIK; 1 % upfront fee and up to 6.25 % end-of-term; no amortization.
Convertible clean-up: $150 m 2021 unsecured converts will be exchanged鈥�$25 m converts to common, $125 m plus accrued interest paid in cash鈥攔emoving a large overhang.
New convert issue: Company to sell $35 m senior unsecured converts (55-month term, 5 % OID, 5 % coupon; 7 % PIK option year 1) convertible at $1.80, subject to shareholder approval.
Private placement: $27.7 m raised via 13.23 m common shares and 0.524 m Series A preferred (auto-converts to 5.24 m common) at $1.50. Proceeds earmarked for working capital. All deals target 12 Aug 25 closing; company will seek shareholder and resale-registration approvals.
Heron Therapeutics, Inc. (HRTX) 鈥� Form 4 insider filing
EVP & Chief Development Officer William P. Forbes reported the vesting and automatic conversion of 3,874 restricted stock units (RSUs) into common shares on 07/19/2025 (transaction code 鈥淢鈥�). No shares were sold, and the RSUs carried a $0.00 exercise price. Following the conversion, Forbes鈥� direct common-stock holdings increased to 138,940 shares. He still holds 38,743 unvested RSUs, which continue to vest quarterly through the original 01/19/2028 schedule. No other equity instruments or derivative transactions were disclosed.
- No cash proceeds were generated; the transaction simply moved shares from the derivative column to direct ownership.
- The filing does not indicate any open-market purchases or dispositions, suggesting the move is part of a pre-set equity-compensation plan.
Form 4 filing for Heron Therapeutics, Inc. (HRTX) discloses that Executive Vice President & Chief Financial Officer Ira Duarte converted 3,874 Restricted Stock Units (RSUs) into an equal number of common shares on 07/19/2025 (transaction code M).
Following the conversion, Duarte directly owns 152,523 HRTX common shares and retains 38,743 unvested RSUs. The RSUs originally granted on 01/19/2024 vest in 16 equal quarterly instalments; the reported tranche represents one of these scheduled releases. No shares were sold and no cash price is indicated (exercise price $0), so total insider ownership increased by the same amount as shares acquired.
No other non-derivative or derivative transactions were reported. This appears to be a routine vesting/settlement event rather than an open-market purchase or disposition.
FAQ
What is the current stock price of Heron Therapeutics (HRTX)?
What is the market cap of Heron Therapeutics (HRTX)?
